Cosmo Pharmaceuticals - Public Comps and Valuation Multiples

Cosmo Pharmaceuticals Overview

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology, and health tech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. The product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, and CB-01-33.

Founded

1997

HQ

Employees

322

Website

cosmopharma.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
Vertical AI Applications
BioTech
DeepTech
B2B SaaS

Financials

LTM Revenue $141M

LTM EBITDA $56.3M

EV

$2.3B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Cosmo Pharmaceuticals Financials

As of February 2026, Cosmo Pharmaceuticals reported last 12-month revenue of $141M and EBITDA of $56.3M.

In the same period, Cosmo Pharmaceuticals generated $85.3M in LTM gross profit and $23.5M in net income.

See Cosmo Pharmaceuticals valuation multiples based on analyst estimates

Cosmo Pharmaceuticals P&L

In the most recent fiscal year, Cosmo Pharmaceuticals reported revenue of $343M and EBITDA of $213M.

Cosmo Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Cosmo Pharmaceuticals valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$141M	XXX	$343M	XXX	XXX	XXX
Gross Profit	$85.3M	XXX	$317M	XXX	XXX	XXX
Gross Margin	61%	XXX	93%	XXX	XXX	XXX
EBITDA	$56.3M	XXX	$213M	XXX	XXX	XXX
EBITDA Margin	40%	XXX	62%	XXX	XXX	XXX
EBIT	$28.2M	XXX	$199M	XXX	XXX	XXX
EBIT Margin	20%	XXX	58%	XXX	XXX	XXX
Net Profit	$23.5M	XXX	$171M	XXX	XXX	XXX
Net Margin	17%	XXX	50%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Cosmo Pharmaceuticals including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $141M. EBITDA for the last twelve months was $56.3M. In the most recent fiscal year, Cosmo Pharmaceuticals achieved $343M in revenue and $213M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$141M	Analyst estimates available to subscribers	$343M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$85.3M	Analyst estimates available to subscribers	$317M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	60.7% gross margin	Analyst estimates available to subscribers	92.6% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$56.3M	Analyst estimates available to subscribers	$213M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	40.0% EBITDA margin	Analyst estimates available to subscribers	62.1% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$28.2M	Analyst estimates available to subscribers	$199M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	20.1% EBIT margin	Analyst estimates available to subscribers	58.1% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$23.5M	Analyst estimates available to subscribers	$171M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	16.7% net profit margin	Analyst estimates available to subscribers	49.9% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Cosmo Pharmaceuticals

This financial data table provides comprehensive performance metrics for Cosmo Pharmaceuticals, a company based in Switzerland. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Cosmo Pharmaceuticals generated $141M in revenue over the last twelve months.
The company achieved $56.3M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $85.3M.
Net income over the last twelve months reached $23.5M.

Fiscal Year Performance

In the most recent fiscal year, Cosmo Pharmaceuticals reported $343M in total revenue.
Fiscal year EBITDA was $213M.
The company maintained a gross profit margin of 92.6% in the most recent fiscal year.
EBITDA margin for the fiscal year was 62.1%.
Net profit margin reached 49.9% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Cosmo Pharmaceuticals. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Cosmo Pharmaceuticals Stock Performance

Cosmo Pharmaceuticals has current market cap of CHF 1.9B (or $2.5B), and EV of CHF 1.8B (or $2.3B).

Market Cap Evolution

Cosmo Pharmaceuticals Stock Data

As of March 4, 2026, Cosmo Pharmaceuticals's stock price is CHF 115 (or $147).

See Cosmo Pharmaceuticals trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.3B	$2.5B	XXX	XXX	XXX	XXX	$1.60

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Cosmo Pharmaceuticals Valuation Multiples

Cosmo Pharmaceuticals's trades at 15.2x EV/Revenue multiple, and 37.9x EV/EBITDA.

See valuation multiples for Cosmo Pharmaceuticals and 15K+ public comps

Cosmo Pharmaceuticals Financial Valuation Multiples

As of March 4, 2026, Cosmo Pharmaceuticals has market cap of $2.5B and EV of $2.3B.

Equity research analysts estimate Cosmo Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Cosmo Pharmaceuticals has a P/E ratio of 96.2x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$2.5B	XXX	$2.5B	XXX	XXX	XXX
EV (current)	$2.3B	XXX	$2.3B	XXX	XXX	XXX
EV/Revenue	15.2x	XXX	15.2x	XXX	XXX	XXX
EV/EBITDA	37.9x	XXX	37.9x	XXX	XXX	XXX
EV/EBIT	75.5x	XXX	75.5x	XXX	XXX	XXX
EV/Gross Profit	25.0x	XXX	n/a	XXX	XXX	XXX
P/E	96.2x	XXX	96.2x	XXX	XXX	XXX
EV/FCF	91.5x	XXX	91.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Cosmo Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Cosmo Pharmaceuticals Margins & Growth Rates

Cosmo Pharmaceuticals's last 12 month revenue growth is 19%

Cosmo Pharmaceuticals's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.4M for the same period.

Cosmo Pharmaceuticals's rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Cosmo Pharmaceuticals's rule of X is 88% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Cosmo Pharmaceuticals and other 15K+ public comps

Cosmo Pharmaceuticals Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	19%	XXX	11%	XXX	XXX	XXX
EBITDA Margin	40%	XXX	40%	XXX	XXX	XXX
EBITDA Growth	59%	XXX	41%	XXX	XXX	XXX
Rule of 40	45%	XXX	59%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	88%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$1.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.4M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	0%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	0%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	34%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial